Selected article for: "ACEi enzyme converting and angiotensin receptor"
Author: Zhichao Feng; Jennifer Li; Shanhu Yao; Qizhi Yu; Wenming Zhou; Xiaowen Mao; Huiling Li; Wendi Kang; Xin Ouyang; Ji Mei; Qiuhua Zeng; Jincai Liu; Xiaoqian Ma; Pengfei Rong; Wei Wang
Title: The Use of Adjuvant Therapy in Preventing Progression to Severe Pneumonia in Patients with Coronavirus Disease 2019: A Multicenter Data Analysis
  • Document date: 2020_4_10
    • ID: k65501xp_8
    Snippet: Inhibition of the spike glycoprotein (S-protein) may also be a viable target and has recently garnered increasing interest -particularly the potential interactions with angiotensinogen converting enzyme 2 (ACE2). It is proposed that the binding of the SARS-CoV-2 S-protein to the functional receptor ACE2 results in proteolytic cleavage by type II transmembrane serine proteases (TMPRSS2). [12] [13] [14] There has been considerable interest and deba.....
    Document: Inhibition of the spike glycoprotein (S-protein) may also be a viable target and has recently garnered increasing interest -particularly the potential interactions with angiotensinogen converting enzyme 2 (ACE2). It is proposed that the binding of the SARS-CoV-2 S-protein to the functional receptor ACE2 results in proteolytic cleavage by type II transmembrane serine proteases (TMPRSS2). [12] [13] [14] There has been considerable interest and debate regarding the risk of severe COVID-19 pneumonia in patients on angiotensinogen converting enzyme inhibitors (ACEI) or angiotensin receptor blocker (ARB) therapy, presumably through the modulation of ACE2 expression. 4, 15, 16 The role of ACEI and ARB in COVID-19 infection remains controversial -as the data is not adjusted for confounding factors of age and other comorbidities to definitively show that ACEI or ARB are independently associated with worse outcomes -and of course, this does not show causality either. 17 Hence, various independent medical societies have put out position statements that recognize the potential risks but given the current quality of evidence, recommend against inappropriate cessation or switch from ACEI/ARB therapy for hypertension, given its proven benefits. 18, 19 Therefore, the objective of this study was to investigate the role of several adjuvant treatments in preventing severe pneumonia in COVID-19 patients from seven cities in Hunan province, China.

    Search related documents:
    Co phrase search for related documents
    • ACEI ARB therapy and angiotensinogen converting: 1
    • ACEI ARB therapy and ARB ACEI role: 1, 2
    • ACEI ARB therapy and ARB therapy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • ACEI ARB therapy and China Hunan province: 1
    • ACEI ARB therapy and converting enzyme: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • adjuvant treatment and ARB therapy: 1
    • adjuvant treatment and converting enzyme: 1, 2, 3, 4, 5, 6
    • angiotensinogen converting and ARB therapy: 1
    • angiotensinogen converting and converting enzyme: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • ARB ACEI role and converting enzyme: 1, 2, 3, 4, 5
    • ARB therapy and China Hunan province: 1
    • ARB therapy and converting enzyme: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • China Hunan province and converting enzyme: 1
    • considerable interest and converting enzyme: 1, 2, 3